News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Six Flags Entertainment Corporation (NYSE:FUN), North America's largest regional amusement-resort operator, has acquired ArieForce One, the celebrated steel roller coaster that captured the imagination of
Filed: 2026-09-08 AccNo: 0001104659-26-105666 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-08 AccNo: 0001493152-26-041699 Size: 278 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Franklin Templeton, Inc. ("Franklin Templeton") (NYSE:BEN), through its leading real estate subsidiary Clarion Partners, LLC, ("Clarion"), is pleased to announce that it has entered into a definitive
Arm Holdings PLC (NASDAQ: ARM) CEO Rene Haas said AI could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure.
Filed: 2026-09-08 AccNo: 0001104659-26-105662 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
The approximately $3.033 million reduction from the September 30, 2025 balance represents roughly 65% of the previously reported amount and marks meaningful progress in strengthening the Company’s balance sheet and
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $115 to $100.
Signet Jewelers reports Q2 results Sept. 9; analysts expect $1.74 EPS and $1.53B revenue. Its 1.64% yield requires $365,596 for $500 monthly.
NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. IONS: -13% | Ionis Pharmaceuticals shares are trading lower amid
Filed: 2026-09-08 AccNo: 0001501697-26-000072 Size: 158 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Target has surged 68% year-to-date while Walmart declined 4%, but the article argues Target is the better buy in September. Despite Target's recent momentum under new CEO Michael Fiddleke and positive comparable sales growth, Walmart remains a recession-resilient juggernaut with superior long-term performance. Target trades at a lower P/E ratio (17x vs 39x) and offers a higher dividend yield (2.8% vs 0.9%), while Walmart has demonstrated more consistent revenue growth and operational excellence over decades.
Alphabet and Meta Platforms are compared as advertising giants pursuing AI investments. While Meta is cheaper and growing faster, Alphabet has a more sound AI strategy with its profitable cloud computing business. Alphabet's AI path appears to be working better than Meta's open-source, non-monetizable approach, making Alphabet the better investment despite Meta's current valuation advantage.
NovaBridge Biosciences announced the appointment of Martin Dewhurst, a veteran healthcare executive with over 30 years of experience, to its Board of Directors as an independent director and member of both the Audit and Compensation Committees. Dewhurst brings extensive governance and strategic expertise from his tenure at McKinsey & Company and multiple board positions across biotech, biopharma, and healthcare companies.
Daniel Masters, Co-Founder and Non-Executive Director of CoinShares, has adopted a Rule 10b5-1 trading plan to sell up to 4.78 million shares (3.6% of outstanding shares) through September 2026 to November 2027. The majority of sales (3.28 million shares) complete a 2023-2024 financing arrangement, while 1.5 million shares represent personal diversification. An additional 11 million shares are subject to limit orders at prices between $10-$20. Masters will retain approximately 15.3% ownership after all planned sales, remaining a significant shareholder.
Rigetti Computing has secured a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS Act to accelerate R&D in superconducting quantum computing. The funds will support three key projects: miniaturizing readout electronics, expanding cryogenic capacity, and developing high-connectivity chip architectures. The Department will receive a minority equity stake in Rigetti as part of the agreement.
Crypto ETFs are experiencing significant inflows, with $2.1 billion in net inflows in the week ended Aug. 28. The author highlights three altcoins as investment opportunities: Solana (benefiting from supply reduction via SGP-0002 proposal), Zcash (which resolved critical security vulnerabilities and launched its first spot ETF), and Hyperliquid (a DEX that activated a new revenue-sharing deal with Coinbase and Circle to fund coin buybacks).
DraftKings has extended its agreement with Integrity Compliance 360 (IC360) to deploy a comprehensive suite of integrity and compliance technologies across its sportsbook and prediction market platforms. The integration marks the first single-operator deployment of IC360's full technology stack, including Integrity Monitoring, ProhiBet, ProhiTrade, and ProhiBet Bad Actors, aimed at combating athlete harassment and market manipulation.
The article examines the 'September Effect,' a historical pattern where the S&P 500 has declined more often in September than any other month, averaging a 1.1% decline since 1928. However, historical data from the past decade shows that investors who continued investing through September downturns were rewarded with significant gains over the medium to long term, suggesting that market timing is ineffective and investors should maintain their investment strategy regardless of seasonal patterns.
NRx Pharmaceuticals announced that its management team, led by CEO Jonathan Javitt, will participate in three investor conferences in September 2026: Moody Capital Solutions Disruptive Growth & Life Sciences Conference (Sept 9), Cantor Global Healthcare Conference (Sept 11), and H.C. Wainwright 28th Annual Global Investment Conference (Sept 14). The company is a clinical-stage biopharmaceutical firm developing NMDA platform therapeutics for CNS disorders including suicidal depression, chronic pain, and PTSD.
Nkarta, Inc. announced selection for three scientific presentations at ACR Convergence 2026 in November, including two oral presentations on NKX019's safety profile and clinical activity in idiopathic inflammatory myopathy, and one poster presentation on systemic sclerosis. The company is advancing NKX019, an allogeneic CAR-NK cell therapy targeting CD19 in B-cell-mediated autoimmune diseases, with enrollment ongoing in the Ntrust Phase 1/2 clinical trials across multiple indications.
Cloverleaf Bio, a Yale spinout RNA therapeutics company, closed a $33 million oversubscribed seed round led by 4BIO Capital with strategic participation from AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund. The funding will advance the company's engineered tRNA platform for cancer treatment, with lead programs targeting hepatocellular carcinoma and colorectal cancer. Preclinical data shows the platform demonstrates superior potency and selectivity for cancer cells over healthy tissue.
Editas Medicine announced the appointment of Dan Ory, M.D., as Chief Medical Officer effective September 8, 2026. Dr. Ory brings over 25 years of experience in cardiovascular and genetic medicine, previously serving as CMO at Arbor Biotechnologies and Casma Therapeutics. He will oversee clinical development strategy as Editas advances EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia treatment, toward clinical trials.
Infex Therapeutics announced Phase IIa data for RESP-X, a first-in-class anti-virulence monoclonal antibody targeting Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis patients. The drug demonstrated a significant reduction in annualized exacerbation rates from 3.4 to 1.2, with only one exacerbation meeting clinical criteria observed across all treated patients. The data supports progression to a larger efficacy study.
To our shareholders, customers, and partners,I want to begin by thanking you for your continued support and confidence in Cyngn. Cyngn exists to help the world's largest industrial operations move materials
Needham analyst Laura Martin reiterates Apple (NASDAQ:AAPL) from Hold to Hold.
The new authorization reflects the Company’s confidence in its business strategy, financial outlook and ability to generate sustainable free cash flow, while providing an additional avenue to create long-term value for
CNBC traders picked FTAI Aviation, KLA and Oracle as final trades, while praising NVIDIA’s Hugging Face deal.